Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mustang Bio, Inc

1.40
-0.0400-2.78%
Post-market: 1.450.0500+3.57%19:51 EDT
Volume:62.05K
Turnover:88.60K
Market Cap:3.69M
PE:-0.02
High:1.49
Open:1.44
Low:1.38
Close:1.44
Loading ...

Mustang Bio trading halted, news pending

TIPRANKS
·
16 Jan

Mustang Bio files to sell common stock and warrants, no amount given

TIPRANKS
·
16 Jan

BUZZ-Mustang Bio falls after announcement of reverse stock split

Reuters
·
14 Jan

Mustang Bio Inc - Stock to Begin Trading on Split-Adjusted Basis Jan 16, 2025

THOMSON REUTERS
·
14 Jan

Mustang Bio Announces Reverse Stock Split

GlobeNewswire
·
14 Jan

Mustang Bio's Interim CFO Resigns After 10 Months

Dow Jones
·
16 Nov 2024

BRIEF-Mustang Bio Says On Nov 12, James Murphy Resigned As Interim CFO

Reuters
·
16 Nov 2024

Mustang Bio: Appointed Manuel Litchman, President & CEO, as Interim CFO

THOMSON REUTERS
·
16 Nov 2024

Mustang Bio: on Nov 12, James Murphy Resigned as Interim CFO

THOMSON REUTERS
·
16 Nov 2024

Mustang Bio receives positive listing determination from Nasdaq

TIPRANKS
·
12 Nov 2024

Mustang Bio Inc - Extension Granted to Meet $1.00 Bid Price Requirement Through Jan 31, 2025

THOMSON REUTERS
·
12 Nov 2024

Mustang Bio Receives Positive Listing Determination From Nasdaq

THOMSON REUTERS
·
12 Nov 2024

Mustang Bio Gets FDA Orphan Drug Designation for MB-108 in Malignant Glioma Treatment

MT Newswires Live
·
08 Nov 2024

Mustang Bio - Mb-108 (Hsv-1 Oncolytic Virus) Is Active and Well Tolerated in Patients With Recurrent Glioblastoma in Ongoing Phase 1 Clinical Trial

THOMSON REUTERS
·
07 Nov 2024

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for Mb-108 (Hsv-1 Oncolytic Virus) to Treat Malignant Glioma

THOMSON REUTERS
·
07 Nov 2024

Mustang Bio Secures $4M through Strategic Warrant Agreement

TipRanks
·
27 Oct 2024